Scinai reports doubling of CDMO revenue and strategic expansion via Recipharm acquisition
Scinai Immunotherapeutics (NASDAQ:SCNI) reported its financial and operational results for the fiscal year ended December 31, 2025, on Wednesday, April 1, 2026.











